CalciMedica, Inc. (CALC)

NASDAQ: CALC · Real-Time Price · USD
2.807
+0.047 (1.69%)
Dec 23, 2024, 10:48 AM EST - Market open
1.69%
Market Cap 37.84M
Revenue (ttm) n/a
Net Income (ttm) -13.59M
Shares Out 13.48M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,608
Open 2.770
Previous Close 2.760
Day's Range 2.770 - 2.835
52-Week Range 2.050 - 8.380
Beta n/a
Analysts Strong Buy
Price Target 18.20 (+548.45%)
Earnings Date Nov 13, 2024

About CALC

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an or... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CALC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CALC stock is "Strong Buy." The 12-month stock price forecast is $18.2, which is an increase of 548.45% from the latest price.

Price Target
$18.2
(548.45% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

LA JOLLA, Calif. , Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium releas...

4 weeks ago - PRNewsWire

CalciMedica Announces Presentations at Upcoming Medical Meetings

Prof. Robert Sutton to  deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting Poster presentation on P...

4 weeks ago - PRNewsWire

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in a position to initiate Phase 3 program in ...

5 weeks ago - PRNewsWire

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

LA JOLLA, Calif. , Nov. 7, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-ac...

6 weeks ago - PRNewsWire

CalciMedica Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium relea...

7 weeks ago - PRNewsWire

CalciMedica Announces Proposed Public Offering of Common Stock

LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium relea...

7 weeks ago - PRNewsWire

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium d...

7 weeks ago - PRNewsWire

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m.

7 weeks ago - PRNewsWire

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

LA JOLLA, Calif. , Oct. 16, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calci...

2 months ago - PRNewsWire

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

LA JOLLA, Calif. , Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calci...

3 months ago - PRNewsWire

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE...

4 months ago - PRNewsWire

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif. , July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or th...

5 months ago - PRNewsWire

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

LA JOLLA, Calif. , July 8, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release...

6 months ago - PRNewsWire

CalciMedica Set to Join Russell Microcap® Index

LA JOLLA, Calif., July 1, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-...

6 months ago - PRNewsWire

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper...

6 months ago - PRNewsWire

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m.

6 months ago - PRNewsWire

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Last patient enrolled in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); topline data expected in 2Q 2024 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to in...

7 months ago - PRNewsWire

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

Collaborators from Cedars-Sinai to present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis (AP) LA JOLLA, Calif., May 7, 2024 /PRNewswire/ -- CalciMedic...

8 months ago - PRNewsWire

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Full target enrollment of 216 patients achieved  Topline data from CARPO expected in 2Q 2024  LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinic...

8 months ago - PRNewsWire

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024  Auxora granted Investigational New Drug clearance by the FDA for Phase 2 tria...

9 months ago - PRNewsWire

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Therapeutic treatment with Auxora shown to hasten the recovery of kidney function and improve survival in a rat model of acute kidney injury (AKI) Preclinical results are consistent with clinical obse...

10 months ago - PRNewsWire

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Preclinical data show that therapeutic treatment with Auxora in a rat model of AKI improves kidney function as measured by glomerular filtration rate LA JOLLA, Calif. , Feb. 28, 2024 /PRNewswire/ -- C...

10 months ago - PRNewsWire

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Phase 2 trial, expected to begin in 1H 2024, aims to address the unmet medical need of patients suffering from stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, a c...

11 months ago - PRNewsWire

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

LA JOLLA, Calif. , Feb. 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calciu...

11 months ago - PRNewsWire

CalciMedica Announces Private Placement of up to Approximately $55 Million

$20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million Upfront net proceeds to provide fun...

1 year ago - PRNewsWire